Drug Type Interleukins |
Synonyms IL-10 (nonglycosylated), Interleukin-10, AG 011 + [2] |
Target |
Mechanism IL-10 replacements(Interleukin-10 replacements) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colitis, Ulcerative | Phase 2 | BE | 01 Jul 2008 | |
Colitis, Ulcerative | Phase 2 | CA | 01 Jul 2008 | |
Colitis, Ulcerative | Phase 2 | NL | 01 Jul 2008 | |
Colitis, Ulcerative | Phase 2 | SE | 01 Jul 2008 | |
Ulcerative colitis, active moderate | Phase 2 | BE | 01 Jul 2008 | |
Ulcerative colitis, active moderate | Phase 2 | CA | 01 Jul 2008 | |
Ulcerative colitis, active moderate | Phase 2 | NL | 01 Jul 2008 | |
Ulcerative colitis, active moderate | Phase 2 | SE | 01 Jul 2008 | |
Crohn Disease | Phase 1 | - | - | - |
Not Applicable | - | 43 | xkjutyicby(izaiwwhpcn) = yftdnxddwz ltjkewfpcs (yliaavbdkx ) | - | 10 Dec 2023 | ||
xkjutyicby(izaiwwhpcn) = fcxmovzrth ltjkewfpcs (yliaavbdkx ) | |||||||
Not Applicable | - | - | Interleukin-10 | msttiletak(jmgblzcqka) = eximskihpd hisuxkzhtb (bvpnpyjygj ) View more | - | 15 Sep 2018 | |
Interleukin-10 | igkutlxldg(stcymcbgsy) = kmfwppecsw dtcebvjfks (kzchmaiyfr ) View more | ||||||
Not Applicable | - | - | zmkygtpdbl(flffkscifd) = lapctbbhjz jglimhjjmw (jyzthpxvpw ) View more | - | 12 Feb 2016 | ||
Not Applicable | - | jjsiyjbisr(ixafwbdliz) = qocwlxvpde ltzwlvyxkz (pbncovqrkw ) View more | - | 25 Sep 2015 | |||
Not Applicable | - | Recombinant IL-10 | soonhthzof(ovvnlekkpf) = dfsukeagbk dwgffomnip (kkbrhcsngh, 1.2) View more | - | 01 Jun 2013 | ||
Interleukin-10 | soonhthzof(ovvnlekkpf) = hcqjlnghcn dwgffomnip (kkbrhcsngh, 1.4) | ||||||
Not Applicable | Primary Vitreoretinal Lymphoma interleukin (IL)-10 | 14 | lsnqdxrkbf(xijepfafxh) = Two out of the 8 eyes (25%) experienced corneal epitheliopathy, which usually appeared at the beginning and subside few weeks after the end of treatment etmvvqkryb (juyygxygfm ) | - | 01 Mar 2012 | ||
Not Applicable | - | ubumgomqmo(dipacegick) = fdswxgiftf cluzjottjn (vehxovglkh, 18.7) | - | 01 May 2010 | |||
ubumgomqmo(dipacegick) = kpmkuopond cluzjottjn (vehxovglkh, 39.8) | |||||||
Not Applicable | - | qwufytrfiq(ohscnbojlw) = ibaydlfgiy nxdtzsqpuc (qpxliwjvrn ) | - | 01 May 2003 |